Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2000-05-15 | Forward | 2:1 |
Alkermes plc is a biopharmaceutical company developing and commercializing treatments for mental health, addiction, and multiple sclerosis, with products like ARISTADA, VIVITROL, and VUMERITY, and collaborations with Janssen.

LUMRYZ, an extended-release oral suspension for narcolepsy symptoms, was acquired by Alkermes in 2026 through Avadel Pharmaceuticals, marking a strategic entry into the sleep medicine market.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Product | $317.42M | — | $338.11M ▲ | $411.72M ▲ |
![]() | Manufactured Product And Royalty | — | $229.24M | — | — |
![]() | Vivitrol | $121.13M | $225.13M ▲ | $112.43M ▼ | $124.45M ▲ |
![]() | Aristada And Aristada Initio | $98.05M | $170.7M ▲ | $93.82M ▼ | $96.72M ▲ |
![]() | L Y B A L V I | $98.25M | — | $92.36M ▼ | $93.98M ▲ |
| Map | REGION | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $931.99M | $1.49B ▲ | $1.41B ▼ | $1.37B ▼ |
![]() | Foreign Country Excluding Specified Country | $177.97M | $170.29M ▼ | $146.18M ▼ | $102.36M ▼ |
![]() | IRELAND | $1.83M | $1.18M ▼ | $1.29M ▲ | $754K ▼ |
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
ARWR | $84.91 | COMPARE |
KYMR | $118.15 | COMPARE |
PTGX | $144.33 | COMPARE |
PCVX | $59.84 | COMPARE |
TGTX | $53.93 | COMPARE |
PTCT | $70.09 | COMPARE |
CRSP | $57.72 | COMPARE |
ACAD | $29.11 | COMPARE |